New immune drug IMA401 takes on Hard-to-Treat cancers

NCT ID NCT05359445

Ongoing Disease control Sponsor: Immatics Biotechnologies GmbH Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times

Summary

This early-phase trial tests a new drug called IMA401, which helps the immune system attack cancer cells. It is for adults with advanced solid tumors (like lung or head and neck cancer) that have come back or stopped responding to treatment. The study checks safety, the right dose, and whether adding another immune drug (pembrolizumab) works better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Charité Universitaetsmedizin Berlin KöR, Klinik fuer Haematologie und Onkologie

Berlin, 12203, Germany
Goethe Universitaetsklinikum Frankfurt AöR, Medizinische Klinik II

Frankfurt am Main, Hesse, 60590, Germany
Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III

Chemnitz, Saxony, 09116, Germany
Klinikum Nuernberg, Klinik fuer Innere Medizin 5, Abteilung Onkologie/Haematologie

Nuremberg, Bavaria, 90419, Germany
Klinikum rechts der Isar der TU Muenchen AöR, Klinik und Poliklinik fuer Innere Medizin III

Munich, Bavaria, 81675, Germany
Marien Hospital Duesseldorf GmbH, Klinik fuer Onkologie/Haematologie und Palliativmedizin

Düsseldorf, North Rhine-Westphalia, 40479, Germany
Medizinische Hochschule Hannover, Klinik fuer Haematologie, Haemostaseologie, Onkologie und Stammzelltransplantation

Hanover, Lower Saxony, 30625, Germany
Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie

Heidelberg, Baden-Wurttemberg, 69126, Germany
Universitaet Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)

Leipzig, Saxony, 04103, Germany
Universitaetsklinikum C. - G. - Carus Dresden, Technische Universitaet Dresden AöR, NCT/UCC Early Clinical Trial Unit

Dresden, Saxony, 01307, Germany
Universitaetsklinikum Erlangen AöR, Interdisciplinary Clinical Trial Unit with ECTU

Erlangen, Bavaria, 91054, Germany
Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten

Heidelberg, Baden-Wurttemberg, 69120, Germany
Universitaetsklinikum Muenster AöR, Medizinische Klinik A

Münster, North Rhine-Westphalia, 48149, Germany
Universitaetsklinikum Regensburg AöR, Klinik fuer Innere Medizin 3

Regensburg, Bavaria, 93053, Germany
Universitaetsklinikum Schleswig- Holstein, Campus Kiel, Medizinische Klinik II Haematologie und Onkologie, Karl-Lennert Tumorzentrum

Kiel, Schleswig-Holstein, 24105, Germany
Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen

Tübingen, Baden-Wurttemberg, 72076, Germany
Universitaetsklinikum Ulm AöR, ECTU-Early clinical Trials Unit Universitaetsklinikum Ulm Comprehensive Cancer Center Ulm_CCCU

Ulm, Baden-Wurttemberg, 89081, Germany
Universitaetsklinikum Wuerzburg AöR, Interdisziplinaeres Studienzentrum mit ECTU

Würzburg, Bavaria, 97078, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, III. Medizinische Klinik

Mainz, Rhineland-Palatinate, 55131, Germany
Universitätsklinikum Bonn AöR, Medizinische Klinik IIII

Bonn, North Rhine-Westphalia, 53127, Germany

Conditions

Explore the condition pages connected to this study.

CANCER RECURRENT CANCER RECURRENT CANCER REFRACTORY CANCER SOLID TUMOR, ADULT